Literature DB >> 2701835

Optimising oral rehydration solution composition for the children of Europe: clinical trials.

R M da Cunha Ferreira1.   

Abstract

Clinical trials testing different oral rehydration solutions (ORS) are reviewed. The effects of individual components and their concentrations are analysed in order to establish margins of safety for the composition of the ideal ORS for children in Europe. Glucose is the solute of choice for ORS and concentrations of 70-140 mmol/l are adequate. Glucose may be replaced by sucrose or glucose polymers. "Low" sodium concentrations (35-60 mmol/l) are advised for rehydration and maintenance in acute non-cholera diarrhoea, for children of all ages, including neonates, and for any degree of dehydration except shock. Although intended for children who are not malnourished, the European ORS should have an adequate potassium concentration (20-30 mmol/l), namely the same concentration as found in WHO-ORS. Chloride concentration depends upon other constituents of ORS, namely sodium and potassium, but the range of 30-90 mmol/l is considered to be adequate. Base or base precursors are not required for correction of acidosis except in the severe cases that always need intravenous replacement. A relatively low osmolality seems advisable.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2701835     DOI: 10.1111/j.1651-2227.1989.tb11319.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand Suppl        ISSN: 0300-8843


  3 in total

1.  Randomised double blind study of hypotonic oral rehydration solution in diarrhoea.

Authors:  T Rautanen; S Kurki; T Vesikari
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

Review 2.  Management of gastroenteritis in early childhood.

Authors:  A Davies; H R Jenkins
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

3.  Randomised double blind trial of hypotonic oral rehydration solutions with and without citrate.

Authors:  T Rautanen; E Salo; M Verkasalo; T Vesikari
Journal:  Arch Dis Child       Date:  1994-01       Impact factor: 3.791

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.